Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Inventory (2021 - 2026)

Indivior Pharmaceuticals has reported Inventory over the past 6 years, most recently at $152.0 million for Q1 2026.

  • For Q1 2026, Inventory fell 6.75% year-over-year to $152.0 million; the TTM value through Mar 2026 reached $152.0 million, down 6.75%, while the annual FY2025 figure was $153.0 million, 8.38% down from the prior year.
  • Inventory for Q1 2026 was $152.0 million at Indivior Pharmaceuticals, down from $153.0 million in the prior quarter.
  • Over five years, Inventory peaked at $178.0 million in Q3 2024 and troughed at $114.0 million in Q4 2022.
  • A 5-year average of $151.1 million and a median of $153.0 million in 2025 define the central range for Inventory.
  • Biggest five-year swings in Inventory: surged 32.54% in 2024 and later fell 12.92% in 2025.
  • Year by year, Inventory stood at $114.0 million in 2022, then increased by 10.53% to $126.0 million in 2023, then surged by 32.54% to $167.0 million in 2024, then fell by 8.38% to $153.0 million in 2025, then dropped by 0.65% to $152.0 million in 2026.
  • Business Quant data shows Inventory for INDV at $152.0 million in Q1 2026, $153.0 million in Q4 2025, and $155.0 million in Q3 2025.